GILD Stock Recent News Gilead Sciences (GILD) 106.45 11/09/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 11:42 AM

Gilead Sciences (GILD) 106.45 $GILD

5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 41 mins ago
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), BIIB: 320.75 (-2.72), PTLA: 27.39 (-0.33), GILD: 106.45 (-0.49), CELG: 106.45 (-0.69)

3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.02 (-0.19), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)

Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 196.00 (-1.40), JNJ: 108.20 (-0.81), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)

Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)

Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), DVA: 74.49 (-3.54), GILD: 106.45 (-0.49), SLXP: 91.47 (-47.08), ICPT: 172.59 (-74.39), HUM: 130.58 (-9.29)

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), GILD: 106.45 (-0.49), AZN: 72.88 (+0.03), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14), CELG: 106.45 (-0.69)

Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)

Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 106.45 (-0.49), MFS.VN: 0.085 (-0.005)

Early Glance: Biotechnology companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)

Humana Misses On ObamaCare Spending, Hep C Costs
at Investor's Business Daily - Fri Nov 07, 9:32AM CST
Humana (HUM) narrowed its earnings outlook for the year as its third-quarter revenue and earnings views fell short of analyst expectations on insurance and hepatitis C-related costs. Full-year earnings guidance is now in the range of $7.40-$7.60 per...
GILD: 106.45 (-0.49), AET: 82.29 (-2.41), HUM: 130.58 (-9.29)

Gilead Sciences (GILD) Crosses Pivot Point Resistance at $108.23
Comtex SmarTrend(R) - Fri Nov 07, 8:58AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.16 and have already reached the first level of resistance at $108.23. Analysts will be watching for a cross of the next upside pivot targets of $109.51 and $111.86.
GILD: 106.45 (-0.49)

Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)

Linkage Biosciences Adds to Board Leadership
Marketwired - Fri Nov 07, 7:02AM CST
Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced the election of Mr. Lewis J. Stuart to the company's Board of Directors. The election reflects Linkage's continued focus on expansion in both domestic and international markets.
GILD: 106.45 (-0.49), GHDX: 35.81 (+0.72)

5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.37 (-0.32), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)

Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15)

Critical Alerts For Delta Airlines, ConocoPhillips, Qualcomm, Kinder Morgan and Gilead Sciences Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for DAL, COP, QCOM, KMI and GILD.
KMI: 38.75 (+0.22), GILD: 106.45 (-0.49), DAL: 42.69 (-0.21), QCOM: 69.26 (-1.32), COP: 72.16 (+0.84)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...